Literature DB >> 10806043

Differential expression of egr-1 in osteoarthritic compared to normal adult human articular cartilage.

F L Wang1, J R Connor, R A Dodds, I E James, S Kumar, C Zou, M W Lark, M Gowen, M E Nuttall.   

Abstract

OBJECTIVE: The purpose of this study was to identify genes that are differentially expressed in normal versus osteoarthritic human articular cartilage as either potential novel therapeutic targets or diagnostic markers of this disease.
DESIGN: mRNA was isolated from histologically normal and osteoarthritic adult human articular cartilage. The Differential Display technique was employed which identified differentially expressed genes in the normal and diseased tissue. Northern and reverse Northern hybridization were used to confirm the gene expression pattern. Immunohistochemistry and in-situ hybridization were used to localize expression of Egr-1 protein and mRNA respectively in cartilage.
RESULTS: A transcription factor, early growth response protein-1 (Egr-1) was found to be down-regulated more than six-fold in multiple human OA cartilage samples when compared to normal tissue. Immunohistochemistry indicated that Egr-1 was expressed throughout normal adult cartilage, in deep-, mid- and superficial-zones. In contrast, in OA cartilage there was expression of Egr-1 mRNA and protein only in the chondrocytes undergoing cloning.
CONCLUSIONS: Egr-1 is differentially expressed in OA versus normal cartilage and because of its role in transcriptional activation and repression and regulation of proliferation, differentiation and apoptosis, Egr-1 may play an important role in the pathogenesis of OA. Up-regulation of Egr-1 may therefore provide a novel therapeutic approach for either the prevention or treatment of OA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10806043     DOI: 10.1053/joca.1999.0295

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  6 in total

1.  Comparative analysis of signaling pathways in peripheral blood from patients with Kashin-Beck disease and osteoarthritis.

Authors:  Yujie Ning; Xi Wang; Sen Wang; Xiong Guo
Journal:  Exp Ther Med       Date:  2016-11-07       Impact factor: 2.447

2.  Egr1 deficiency disrupts dynamic equilibrium of chondrocyte extracellular matrix through PPARγ/RUNX2 signaling pathways.

Authors:  Ke Lu; Tian-Shu Shi; Si-Yu Shen; Wan-Li Lu; Jing Wu; Kai-Jia Zhang; Xiao-Bo Zhu; Yong Shi; Xiang-Lin Liu; Fei Yu; Lan Li; Hua-Jian Teng; Xiang Gao; Huang-Xian Ju; Wei Wang; Chao-Jun Li; Qing Jiang; Bin Xue
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

3.  Egr-1 contributes to IL-1-mediated down-regulation of peroxisome proliferator-activated receptor γ expression in human osteoarthritic chondrocytes.

Authors:  Sarah-Salwa Nebbaki; Fatima Ezzahra El Mansouri; Hassan Afif; Mohit Kapoor; Mohamed Benderdour; Nicolas Duval; Jean-Pierre Pelletier; Johanne Martel-Pelletier; Hassan Fahmi
Journal:  Arthritis Res Ther       Date:  2012-03-28       Impact factor: 5.156

4.  Egr-1 increases angiogenesis in cartilage via binding Netrin-1 receptor DCC promoter.

Authors:  Jun Sheng; Da Liu; Xia Kang; Ying Chen; Kai Jiang; Wei Zheng
Journal:  J Orthop Surg Res       Date:  2018-05-29       Impact factor: 2.359

5.  RUNX3, EGR1 and SOX9B form a regulatory cascade required to modulate BMP-signaling during cranial cartilage development in zebrafish.

Authors:  Julia Dalcq; Vincent Pasque; Aurélie Ghaye; Arnaud Larbuisson; Patrick Motte; Joseph A Martial; Marc Muller
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

6.  The immediate early gene product EGR1 and polycomb group proteins interact in epigenetic programming during chondrogenesis.

Authors:  Frank Spaapen; Guus G H van den Akker; Marjolein M J Caron; Peggy Prickaerts; Celine Rofel; Vivian E H Dahlmans; Don A M Surtel; Yvette Paulis; Finja Schweizer; Tim J M Welting; Lars M Eijssen; Jan Willem Voncken
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.